⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614565 | 0.82 | — | — | |
| SCHEMBL27618721 | 0.80 | — | — | |
| SCHEMBL13735546 | 0.79 | IDO1 (0.33) | — | |
| SCHEMBL9799881 | 0.77 | ALDH1A1 (0.34) | — | |
| SCHEMBL546639 | 0.77 | NPSR1 (0.46) | — | |
| SCHEMBL2385331 | 0.76 | — | — | |
| SCHEMBL12655180 | 0.76 | — | — | |
| SCHEMBL169065 | 0.76 | — | — | |
| SCHEMBL2591837 | 0.76 | — | — | |
| SCHEMBL16098683 | 0.75 | IDO1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-115746002-B | Deuterated aza-indolyl amino-pyrazole carboxamide compound and application thereof | 药康众拓(江苏)医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-115746002-B | Deuterated aza-indolyl amino-pyrazole carboxamide compound and application thereof | 药康众拓(江苏)医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| CN-115746002-A | Deuterated azaindoleamino-pyrazole carboxamide compound and application thereof | 药康众拓(江苏)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-0477049-B1 | Amido-3-pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 1999-12-01 | — | — | EP | disclosed |
| US-5744493-A | POSSESS ACTIVITY WITH RESPECT TO THE CENTRAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM AND THE GASTROINTESTINAL SYSTEM | SANOFI (FR) | 1998-04-28 | — | — | US | disclosed |
| US-5744491-A | POSSESS ACTIVITY WITH RESPECT TO THE CENTRAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM AND THE GASTROINTESTINAL SYSTEM | SANOFI (FR) | 1998-04-28 | — | — | US | disclosed |
| US-5635526-A | POSSESSES ACTIVITY WITH RESPECT TO THE CENTRAL NERVOUS SYSTEM, THE CARDIOVASCULAR SYSTEM OR THE GASTROINTESTINAL SYSTEM | SANOFI (FR) | 1997-06-03 | — | — | US | disclosed |
| US-5616592-A | USEFUL FOR DISORDERS OF CARDIOVASCULAR, GASTROINTESTINAL AND PSYCHOLOGICAL DISORDERS | SANOFI (FR) | 1997-04-01 | — | — | US | disclosed |
| US-5607958-A | NEUROTENSIN RECEPTOR BINDERS | SANOFI (FR) | 1997-03-04 | — | — | US | disclosed |
| US-5420141-A | Capable of binding to neurotensin receptor | SANOFI (FR) | 1995-05-30 | — | — | US | disclosed |
| WO-1993007149-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | disclosed |
| EP-0477049-A1 | Amido-3-pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1992-03-25 | — | — | EP | disclosed |
| US-4317823-A | FOR TREATMENT OF GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-03-02 | — | — | US | disclosed |